Literature DB >> 11260081

Interleukin 4 content in chronic lymphocytic leukaemia (CLL) B cells and blood CD8+ T cells from B-CLL patients: impact on clonal B-cell apoptosis.

N E Kay1, L Han, N Bone, G Williams.   

Abstract

B-chronic lymphocytic leukaemia (CLL) clonal B cells are characterized by resistance to apoptosis. We evaluated clonal B cells and blood T cells for interleukin 4 (IL-4) content as IL-4 is able to increase CLL cell resistance to apoptosis. The content of IL-4 in CD8+ T cells of CLL patients (n = 9) ranged from 37% to 63% of the total CD8+ T cells (mean level of 49% +/- 3.4) compared with a range of 5-10% for control CD8+ T cells. Clonal B cells positive for cytoplasmic IL-4 ranged from 1% to 97% (mean value 57.8 +/- 6.9%). CD8+ T cells and clonal B cells secreted detectable levels of IL-4, but only clonal CLL B cells (n = 4) secreted IL-4 in association with increasing cell numbers. Fludarabine (F-ara-AMP, 0.1-100 micromol/ml) was able to downregulate the IL-4 content of CD8+ T cells, but not clonal B-cell IL-4. Culture supernatant from CLL CD8+ T cells decreased the spontaneous apoptotic rate of clonal B cells that was reversed with anti-IL-4 and soluble IL-4 receptor. These findings show that IL-4 is present in the microenvironment of B-CLL. In addition, use of agents that can interfere with IL-4 presentation to clonal B cells can be effective in increasing clonal B-cell apoptosis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11260081     DOI: 10.1046/j.1365-2141.2001.02605.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  8 in total

1.  Chronic lymphocytic leukemia cells induce changes in gene expression of CD4 and CD8 T cells.

Authors:  Güllü Görgün; Tobias A W Holderried; David Zahrieh; Donna Neuberg; John G Gribben
Journal:  J Clin Invest       Date:  2005-06-16       Impact factor: 14.808

2.  Antibodies selected from combinatorial libraries block a tumor antigen that plays a key role in immunomodulation.

Authors:  John R McWhirter; Anke Kretz-Rommel; Alan Saven; Toshiaki Maruyama; Kathleen N Potter; C Ian Mockridge; E Prenn Ravey; Fenghua Qin; Katherine S Bowdish
Journal:  Proc Natl Acad Sci U S A       Date:  2006-01-17       Impact factor: 11.205

3.  Chronic lymphocytic leukaemia cells drive the global CD4+ T cell repertoire towards a regulatory phenotype and leads to the accumulation of CD4+ forkhead box P3+ T cells.

Authors:  K P Piper; M Karanth; A McLarnon; E Kalk; N Khan; J Murray; G Pratt; P A H Moss
Journal:  Clin Exp Immunol       Date:  2011-11       Impact factor: 4.330

Review 4.  Immune reconstitution in chronic lymphocytic leukemia.

Authors:  John C Riches; Alan G Ramsay; John G Gribben
Journal:  Curr Hematol Malig Rep       Date:  2012-03       Impact factor: 3.952

5.  P38 mitogen activated protein kinase expression and regulation by interleukin-4 in human B cell non-Hodgkin lymphomas.

Authors:  Hu Ding; Ali M Gabali; Stephen D Jenson; Megan S Lim; Kojo S J Elenitoba-Johnson
Journal:  J Hematop       Date:  2009-10-21       Impact factor: 0.196

6.  High-content screening identifies kinase inhibitors that overcome venetoclax resistance in activated CLL cells.

Authors:  Sina Oppermann; Jarkko Ylanko; Yonghong Shi; Santosh Hariharan; Christopher C Oakes; Patrick M Brauer; Juan C Zúñiga-Pflücker; Brian Leber; David E Spaner; David W Andrews
Journal:  Blood       Date:  2016-06-13       Impact factor: 22.113

7.  The Hsp90 inhibitor NVP-AUY922-AG inhibits NF-κB signaling, overcomes microenvironmental cytoprotection and is highly synergistic with fludarabine in primary CLL cells.

Authors:  Elisabeth Walsby; Lawrence Pearce; Alan K Burnett; Chris Fegan; Chris Pepper
Journal:  Oncotarget       Date:  2012-05

Review 8.  Involvement of memory T-cells in the pathophysiology of chronic lymphocytic leukemia.

Authors:  Rodolfo Patussi Correia; Flávia Amoroso Matos E Silva; Nydia Strachman Bacal; Paulo Vidal Campregher; Nelson Hamerschlak; Gustavo P Amarante-Mendes
Journal:  Rev Bras Hematol Hemoter       Date:  2014
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.